+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases



Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases



Zeitschrift für Rheumatologie 62(2): 155-160



102 rheumatoid arthritis (RA) and 104 psoriatic arthritis (PsA) patients' records were analysed according to a standardised protocol. Using Cox regression, life-table analysis and log rank test, the effectiveness and toxicity of, and duration of disease modifying antirheumatic drug (DMARD) treatment were compared in RA and PsA. RA patients were treated with gold sodium thiomalate (GST), methotrexate (MTX) and sulphasalazine (SSZ) for a median duration of 35, 72 and 12 months respectively, whereas PsA patients were treated for 12, 12 and 17 months. The differences for GST and MTX were statistically significant (p=0.0043 and 0.0447). Drug toxicity was more frequently seen among patients with PsA (p=0.0023). No difference in efficacy could be proved. Results suggest that there is a significant difference between RA and PsA patients in terms of toxicity of these agents. Therefore, separate treatment strategies are needed, and earlier results with RA may not be directly applicable to PsA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011460566

Download citation: RISBibTeXText

PMID: 12721703

DOI: 10.1007/s00393-003-0458-2


Related references

Termination of disease modifying antirheumatic drugs in psoriatic arthritis. Journal of Rheumatology 28(3): 682-683, 2001

Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 74(2): 474-475, 2015

First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. Annals of the Rheumatic Diseases 73(10): 1905-1906, 2015

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Therapeutics and Clinical Risk Management 13: 583-592, 2017

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Annals of the Rheumatic Diseases 77(9): 1276-1282, 2018

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. Arthritis Care and Research 71(4): 512-520, 2019

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment 20(35): 1-610, 2016

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the Rheumatic Diseases 66(6): 732-739, 2007

Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Current Opinion in Rheumatology 20(3): 251-256, 2008

The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clinical Rheumatology 38(2): 297-305, 2019

FRI0159Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from An Ontario Rheumatoid Arthritis Cohort. Annals of the Rheumatic Diseases 75(Suppl 2): 486.2-487, 2016

Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis. Journal of Rheumatology 40(2): 127-136, 2013

AB0278Early Termination of the First Biological Disease-Modifying Antirheumatic Drugs Therapy Leads to Radiological Progression in Patients with Rheumatoid Arthritis, Irrespective of Subsequent Therapies. Annals of the Rheumatic Diseases 74(Suppl 2): 985.2-985, 2015

The treatment of rheumatoid arthritis with low dose pulse methotrexate--comparative study with other disease modifying antirheumatic drugs. Ryumachi 32(1): 3, 1992

Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. Journal of Rheumatology 35(3): 472-476, 2008